ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Cash Position & Operating Runway : As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments of $314.0 million, with 97,954,172 shares of common stock outstanding. The ...
CABLIVI Market Reports Positive Growth - Strong Momentum Expected to Continue | DelveInsight
DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von ...
‘We’ll be Curry’s of Chinese cars’ says boss of EV firm ‘no-one’s heard of’ but sells cars ‘like Vauxhall for MUCH less’
YOU walk into Currys to buy a Samsung and walk out with a ­WingWang. Because you realise it does the same thing for much less ...
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...
CarsGuide on MSN10h
Is this the next-gen MG4… or an MG3?
A new electric car from MG has been revealed via a Chinese government regulator, but just what the car is could be up for ...
DelveInsight Business Research, LLP: CABLIVI Market Reports Positive Growth - Strong Momentum Expected to Continue | DelveInsight
Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology ...